- Home
- Weight Management & Metabolism
- Retatrutide
Weight Management
Retatrutide
Retatrutide · Investigational molecule
An investigational agonist of the GIP, GLP‑1 and glucagon receptors, currently in clinical trials. It is not an authorised medicine: this page summarises the state of research.
- Partner pharmacy
- Personal assistance
- Discreet delivery
Shipping & Delivery
- Normally dispatched within 24 hours of payment confirmation.
- UPS Express · A$25 · Approx. 7–9 business days
- Registered Mail · A$15 · Approx. 14–20 business days
For research use only.
Not intended for human or animal consumption, nor for medical, personal or diagnostic use. By purchasing this product, you confirm that you are qualified to handle research materials.
What is known so far
Retatrutide is being studied in clinical trials as a single molecule acting on three receptors: GIP, GLP‑1 and glucagon. It has no marketing authorisation. Results from ongoing trials should not be read as proven clinical benefits.
Product information
Patient information leafletNot available: not an authorised medicine
Summary of Product CharacteristicsNot available: not an authorised medicine
Sources
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389:514–526.
- Bajaj HS, et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1). Lancet. 2026;407:2402–2413.
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet. Published online 29 September 2026.
Related
Weight Management 
